Predicting the Response to Immunotherapy Using Artificial Intelligence
A study published in The Lancet Oncology establishes for the first
time that artificial intelligence can process medical images to extract
biological and clinical information. By designing an algorithm and
developing it to analyse CT scan images, medical researchers at Gustave
Roussy, CentraleSupélec, Inserm, Paris-Sud University and TheraPanacea
(spin-off from CentraleSupélec specialising in artificial intelligence
in oncology-radiotherapy and precision medicine) have created a
so-called radiomic signature. This signature defines the level of
lymphocyte infiltration of a tumour and provides a predictive score for
the efficacy of immunotherapy in the patient.
In the future, physicians might thus be able to use imaging to identify biological phenomena in a tumour located in any part of the body without having to perform a biopsy.
Up to now, no marker can accurately identify those patients who will respond to anti-PD-1/PD-L1 immunotherapy in a situation where only 15 to 30% of patients do respond to such treatment. It is known that the richer the tumour environment is immunologically (presence of lymphocytes) the greater the chance that immunotherapy will be effective, so the researchers have tried to characterise this environment using imaging and correlate this with the patients’ clinical response. Such is the objective of the radiomic signature designed and validated in the study published in The Lancet Oncology.
In this retrospective study, the radiomic signature was captured, developed and validated in 500 patients with solid tumours (all sites) from four independent cohorts. It was validated genomically, histologically and clinically, making it particularly robust.
Using an approach based on machine learning, the team first taught the algorithm to use relevant information extracted from CT scans of patients participating in the MOSCATO study1, which also held tumor genome data. Thus, based solely on images, the algorithm learned to predict what the genome might have revealed about the tumour immune infiltrate, in particular with respect to the presence of cytotoxic T-lymphocytes (CD8) in the tumour, and it established a radiomic signature.
This signature was tested and validated in other cohorts including that of TCGA (The Cancer Genome Atlas) thus showing that imaging could predict a biological phenomenon, providing an estimation of the degree of immune infiltration of a tumour.
Then, to test the applicability of this signature in a real situation and correlate it to the efficacy of immunotherapy, it was evaluated using CT scans performed before the start of treatment in patients participating in 5 phase I trials of anti-PD-1/PD-L1 immunotherapy. It was found that the patients in whom immunotherapy was effective at 3 and 6 months had higher radiomic scores as did those with better overall survival.
The next clinical study will assess the signature both retrospectively and prospectively, will use larger numbers of patients and will stratify them according to cancer type in order to refine the signature.
This will also employ more sophisticated automatic learning and artificial intelligence algorithms to predict patient response to immunotherapy. To that end, the researchers are intending to integrate data from imaging, molecular biology and tissue analysis. This is the objective of the collaboration between Gustave Roussy, Inserm, Université Paris-Sud, CentraleSupélec and TheraPanacea to identify those patients who are the most likely to respond to treatment, thus improving the efficacy/cost ratio of the treatment.
// About radiomics
In radiomics, it is considered that imaging (CT, MRI, ultrasound, etc.) not only reveals the organisation and architecture of tissues but also their molecular or cellular composition. The technique involves the use of algorithms to analyse a medical image objectively in order to extract from it information which is invisible to the naked eye, such as the texture of a tumour, its micro-environment, its heterogeneity, etc. For the patient this represents a non-invasive approach that can be repeated over the course of the disease to follow its progress.
DOI : 10.1016/S1470-2045(18)30413-3
1 Results of the MOSCATO study published in Cancer Discovery : http://cancerdiscovery.aacrjournals.org/content/early/2017/03/26/2159-8290.CD-16-1396
Claire Parisel, 220.127.116.11.50.59
Priscille Riviere, 33 18.104.22.168.97
Laurence Wendling, 33 22.214.171.124.15
Catherine Martineau-Huynh, 33 126.96.36.199.65
Cécile Pérol, Tél. 33 1 188.8.131.52
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Guy Carpenter Names Ross Howard Vice Chairman20.11.2018 17:46 | Pressemelding
Guy Carpenter & Company, LLC, a leading global risk and reinsurance specialist and a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), today announced a new leadership appointment from the Jardine Lloyd Thompson Group plc (JLT) reinsurance organization. Effective upon closing of the transaction between Guy Carpenter’s parent company, Marsh & McLennan Companies and JLT, which remains subject to the receipt of certain antitrust and financial regulatory approvals, Ross Howard, Chairman of JLT Re, will become Vice Chairman of Guy Carpenter, reporting to President & CEO Peter Hearn. Mr. Howard will also become a member of Guy Carpenter’s Executive Committee and will be responsible for developing new business opportunities and assisting with client relationships in order to continue the growth of the combined global reinsurance business. Additionally, Mr. Howard will also play a key role in executing the integration of JLT Re with Guy Carpenter. “We are very excited to take
IDEMIA Will Present Its 2018 Quarterly Financial Results to Investors on November 21, 201820.11.2018 17:31 | Pressemelding
IDEMIA, the world leader in Augmented Identity, today announced that it will present its Q3 2018 financial results to investors on Wednesday November 21, 2018. Yann Delabrière (CEO), Frédéric Beylier (COO) and Laurent Lemaire (CFO) will be presenting the financial results and taking questions the same day at 1:00 pm CET (12:00 pm London Time / 7:00 am New York Time). For more information, please refer to our website: http://investors.oberthur.com About IDEMIA OT-Morpho is now IDEMIA, the global leader in Augmented Identity, with the ambition to empower citizens and consumers alike to interact, pay, connect, travel and vote in ways that are now possible in a connected environment. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable t
OCP Announces Date of Third Quarter 2018 Earnings20.11.2018 17:00 | Pressemelding
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter 2018 results on Thursday, November 29, 2018. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 8:30 a.m. EST, 2:30 p.m. Morocco time (GMT+1), and 1:30 p.m. London time (GMT). OCP senior management will host a conference call to discuss third quarter 2018 results at 9:30 a.m. EST, 3:30 p.m. Morocco time (GMT+1), and 2:30 p.m. London time (GMT) on Thursday, November 29, 2018 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing email@example.com About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. O
Arch Insurance Announces Strategic Leadership Changes20.11.2018 15:50 | Pressemelding
Arch Insurance (“Arch”) today announced Hugh Sturgess will assume the role of Chief Executive Officer, Arch Insurance International, effective Jan. 1, 2019, subject to regulatory approvals. Arch Insurance International includes Arch’s insurance operations in Europe, Bermuda and Australia. Mr. Sturgess has been with Arch Insurance since 2005 and is currently President and CEO of Arch Insurance Canada Ltd., where he has strategic and operational responsibility for a multi-line underwriting portfolio. Before joining Arch, Mr. Sturgess held various roles in the financial services industry, including tenures with the Royal Bank of Canada and Chubb Insurance Company of Canada. “Arch Insurance International underwrites a diverse portfolio of specialty insurance solutions across a number of geographies, with a key focus on providing value to our distribution partners and customers,” Mr. Sturgess said. “I look forward to the opportunity to work with our team in continuing to expand the value pr
Takeda Receives Clearance from the European Commission for the Proposed Acquisition of Shire plc20.11.2018 14:33 | Pressemelding
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (“Takeda”) announces that it has received clearance from the European Commission (the “EC”) for the proposed acquisition of Shire plc (“Shire”) announced on May 8, 2018 (the “Acquisition”). The EC’s approval is conditional on Takeda and Shire fulfilling commitments given to the EC in connection with the clearance. Specifically, in relation to the future potential overlap in the area of inflammatory bowel diseases between Takeda’s marketed product Entyvio (vedolizumab) and Shire’s pipeline compound SHP647, Takeda and Shire have committed to divest the pipeline compound SHP647 and certain associated rights. The divestment of SHP647 and certain associated rights is not a condition to the completion of the Acquisition. SHP647 is an exciting pipeline compound
ResMed Elects Harjit Gill to Its Board of Directors20.11.2018 14:05 | Pressemelding
ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service business solutions, today announced it has elected experienced consumer and healthcare executive Harjit Gill to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181120005179/en/ Harjit Gill, BA (Photo: Business Wire) Ms. Gill was elected by shareholders at its annual shareholder meeting last week in Sydney, Australia. Also, announced at that meeting, Gary W. Pace has retired from ResMed’s board after serving on it since July 1994. Ms. Gill’s appointment and Dr. Pace’s retirement both took effect Thursday, November 15. Ms. Gill has more than 25 years’ experience in health and consumer technology products as an executive, investor and regional business leader spanning Asia, Europe and the Middle East. From 1990 to 2015, she worked for Royal Philips as executive vice president and CEO for Phi